We are especially grateful to all study participants; Rai, Director, Lumbini Eye Hospital, Bhairahawa, Nepal; Deborah, Dean of Children’s Hospital Oakland Research Center; Harran Mkocha and the Kongwa Trachoma Project in Kongwa District, Tanzania; and community leaders for generously giving their time. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Thylefors B, Dawson CR, Jones BR, West SK, Taylor HR, 1987. A simple system for the assessment of trachoma and its complications. Bull World Health Organ 65: 477–483.
WHO, 1997. Report of the First Meeting of the WHO Alliance for the Global Elimination of Trachoma. Geneva, Switzerland: World Health Organization.
Bailey R, Duong T, Carpenter R, Whittle H, Mabey D, 1999. The duration of human ocular Chlamydia trachomatis infection is age dependent. Epidemiol Infect 123: 479–486.
Goodhew EB 2014. Longitudinal analysis of antibody responses to trachoma antigens before and after mass drug administration. BMC Infect Dis 14: 216.
Goodhew EB, Priest JW, Moss DM, Zhong G, Munoz B, Mkocha H, Martin DL, West SK, Gaydos C, Lammie PJ, 2012. CT694 and pgp3 as serological tools for monitoring trachoma programs. PLoS Negl Trop Dis 6: e1873.
Horner PJ, Wills GS, Reynolds R, Johnson AM, Muir DA, Winston A, Broadbent AJ, Parker D, McClure MO, 2013. Effect of time since exposure to Chlamydia trachomatis on Chlamydia antibody detection in women: a cross-sectional study. Sex Transm Infect 89: 398–403.
Comanducci M, Manetti R, Bini L, Santucci A, Pallini V, Cevenini R, Sueur JM, Orfila J, Ratti G, 1994. Humoral immune response to plasmid protein pgp3 in patients with Chlamydia trachomatis infection. Infect Immun 62: 5491–5497.
Horner P, Soldan K, Vieira SM, Wills GS, Woodhall SC, Pebody R, Nardone A, Stanford E, McClure MO, 2013. C. trachomatis Pgp3 antibody prevalence in young women in England, 1993–2010. PLoS One 8: e72001.
Gwyn S, Mitchell A, Dean D, Mkocha H, Handali S, Martin DL, 2016. Lateral flow-based antibody testing for Chlamydia trachomatis. J Immunol Methods 435: 27–31.
Banniettis N, Thumbu S, Szigeti A, Chotikanatis K, Braunstein M, Gadir GAE, Hammerschlag M, Kohlhoff S, 2015. Seroprevalence of Chlamydia trachomatis (CT) in inner city children and adolescents: implications for vaccine development. Open Forum Infect Dis 2: 1569.
Wang J, Zhang Y, Lu C, Lei L, Yu P, Zhong G, 2010. A genome-wide profiling of the humoral immune response to Chlamydia trachomatis infection reveals vaccine candidate antigens expressed in humans. J Immunol 185: 1670–1680.
Wills GS, Horner PJ, Reynolds R, Johnson AM, Muir DA, Brown DW, Winston A, Broadbent AJ, Parker D, McClure MO, 2009. Pgp3 antibody enzyme-linked immunosorbent assay, a sensitive and specific assay for seroepidemiological analysis of Chlamydia trachomatis infection. Clin Vaccine Immunol 16: 835–843.
Donati M, Laroucau K, Storni E, Mazzeo C, Magnino S, Di Francesco A, Baldelli R, Ceglie L, Renzi M, Cevenini R, 2009. Serological response to pgp3 protein in animal and human chlamydial infections. Vet Microbiol 135: 181–185.